Literature DB >> 9814687

Mechanisms of autoantibody-mediated thrombosis.

R A Roubey1.   

Abstract

It is widely hypothesized that autoantibodies directly contribute to the prothrombotic state in the antiphospholipid syndrome (APS). The discovery that antiphospholipid autoantibodies are specific for phospholipid-binding plasma proteins (beta2-glycoprotein I, prothrombin, etc.) has allowed a much more precise investigation of the interactions of autoantibodies and antigens, and the effects of these interaction on hemostasis. Recent studies suggest that two types of interactions may be important in the pathophysiology of APS: (1) antibody cross-linking of membrane bound antigens may alter the kinetics of phospholipid-dependent reactions; and (2) antibody cross-linking of antigens bound to cell surface receptors may trigger signal transduction and cellular activation. In light of these findings, previous reports implicating various mechanisms of autoantibody-mediated thrombosis are being re-evaluated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814687     DOI: 10.1177/096120339800700226

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

Review 1.  Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases?

Authors:  Pier Luigi Meroni; Cristina Luzzana; Donatella Ventura
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

Review 2.  Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis.

Authors:  M C Amigo; R García-Torres
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.686

3.  Pathogenesis of Antiphospholipid Syndrome.

Authors:  Borut Bo Ic
Journal:  EJIFCC       Date:  2004-08-31

4.  The clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study.

Authors:  Faruk Ertaș; Oznur Can; Halit Acet; Mert Ozbakkaloglu
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-11-18       Impact factor: 1.426

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.